Literature DB >> 29032271

A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model.

Massimo Martino1, Sabino Ciavarella2, Simona De Summa3, Letteria Russo4, Nicola Meliambro4, Lucrezia Imbalzano4, Giuseppe Alberto Gallo4, Tiziana Moscato4, Giuseppe Messina4, Anna Ferreri4, Maria Cuzzola4, Giuseppe Irrera4, Virginia Naso4, Michele Cimminiello5, Giuseppe Console4, Giacomo Loseto2, Stefania Tommasi3, Attilio Guarini2.   

Abstract

Outpatient autologous stem cell transplantation (ASCT) has proven to be feasible in terms of physical morbidity and mortality outcomes, but little data exist on the impact of this procedure on quality of life (QoL). The purpose of this prospective, observational, longitudinal cohort study was to compare the effects of inpatient (n = 76) and outpatient (n = 64) modes of care on QoL in patients with multiple myeloma who underwent ASCT. Patients were treated according to their preference for the inpatient or outpatient model. QoL was assessed using the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) at baseline (7 days before ASCT; T1) and at days +7 (T2) and +30 (T3) after ASCT. Overall, inpatients achieved higher mean values at each time point (86.05 ± 15.54 at T1, 89.23 ± 19.19 at T2, and 87.96 ± 13.6 at T3) compared with outpatients (85.62 ± 14.51 at T1, 87.42 ± 23.41 at T2, and 83.98 ± 20.2 at T3), although the differences did not reach statistical significance. Inpatients showed higher mean scores than outpatients in physical well-being (7.67 ± 5.7, 15.44 ± 6.34, and 12.96 ± 6.03, respectively, versus 5.89 ± 4.33, 13.92 ± 7.05, and 8.84 ± 6.33, respectively; P < .05). Mean scores on social/family well-being were significantly higher in the outpatient group compared with the inpatient group (22.93 ± 13.29, 21.14 ± 5.31, and 21.64 ± 4.58, respectively, versus 20.59 ± 3.79, 19.52 ± 5.12, and 20.01 ± 3.97, respectively; P = .003). There were no significant between-group differences with respect to functional well-being and emotional status. Among adults at a single institution undergoing ASCT for MM, the use of outpatient care compared with standard transplantation care did not result in improved QoL during transplantation. Further research is needed for replication and to assess longer-term outcomes and implications.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ASCT; Inpatient; Multiple myeloma; Outpatient; Quality of life

Mesh:

Year:  2017        PMID: 29032271     DOI: 10.1016/j.bbmt.2017.09.021

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  7 in total

1.  Current role of high dose chemotherapy in the management of multiple myeloma.

Authors:  Morie A Gertz
Journal:  Leuk Lymphoma       Date:  2018-12-11

2.  Home-Based Hematopoietic Cell Transplantation in the United States.

Authors:  Anthony D Sung; Vinay K Giri; Helen Tang; Krista Rowe Nichols; Meagan V Lew; Lauren Bohannon; Yi Ren; Sin-Ho Jung; Tara Dalton; Amy Bush; Jolien Van Opstal; Alexandra Artica; Julia Messina; Rebecca Shelby; Jennifer Frith; Martha Lassiter; Jill Burleson; Kari Leonard; Ashley S Potter; Taewoong Choi; Cristina J Gasparetto; Mitchell E Horwitz; Gwynn D Long; Richard D Lopez; Stefanie Sarantopoulos; Nelson J Chao
Journal:  Transplant Cell Ther       Date:  2022-01-20

Review 3.  Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) in the Elderly and the Importance of Sport Activity Training.

Authors:  Antonello Sica; Paola Vitiello; Andrea Ronchi; Beniamino Casale; Armando Calogero; Evangelista Sagnelli; Gilca Costa Nachtigal; Teresa Troiani; Renato Franco; Giuseppe Argenziano; Elvira Moscarella; Caterina Sagnelli
Journal:  Int J Environ Res Public Health       Date:  2020-01-29       Impact factor: 3.390

4.  Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors.

Authors:  Jane Koo; Stacy Silverman; Brandon Nuechterlein; Amy K Keating; Michael R Verneris; Nicholas K Foreman; Jean M Mulcahy Levy
Journal:  Bone Marrow Transplant       Date:  2019-02-19       Impact factor: 5.483

Review 5.  Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.

Authors:  Massimo Martino; Annalisa Paviglianiti; Mara Memoli; Giovanni Martinelli; Claudio Cerchione
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244

6.  Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis.

Authors:  Weerapat Owattanapanich; Kittima Suphadirekkul; Chutima Kunacheewa; Patompong Ungprasert; Kannadit Prayongratana
Journal:  BMC Cancer       Date:  2018-11-16       Impact factor: 4.430

7.  An Anecdotal Case Report of Chronic Lymphatic Leukemia with del(11q) Treated with Ibrutinib: Artificial Nourishment and Physical Activity Program.

Authors:  Antonello Sica; Caterina Sagnelli; Alfonso Papa; Massimo Ciccozzi; Evangelista Sagnelli; Armando Calogero; Erika Martinelli; Beniamino Casale
Journal:  Int J Environ Res Public Health       Date:  2020-03-16       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.